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Abstract
Background: Results from increasing numbers of in vitro and in vivo studies have demonstrated that omega 3
fatty acids incorporated in cell culture media or in the diet of the animals can suppress the growth of cancers.
When human clinical trials are initiated to determine the ability of omega 3 fatty acids to alter growth or response
to chemotherapeutic interventions of cancers, it will be essential to determine the omega 3 intake of individuals in
the trial to determine compliance with consumption of the supplement and to correlate with endpoints of
efficacy. We wondered if the fatty acid composition of RBCs might accurately indicate incorporation of omega 3
fatty acids in the WBCs. In this report we determine and compare the changes in fatty acid compositions of red
blood cells and white blood cells in response to consumption of three doses of an omega 3 fatty acid
supplement.
Results: We found that the fraction of omega 3 fatty acids in both red blood cells and white blood cells increased
following consumption of the supplement. There was a linear, dose responsive increase in the fraction of omega 3
fatty acids in red blood cells but the increase in omega 3 in white blood cells was not linear. The magnitude of
increase in omega 3 fatty acids was different between the two cell types.
Conclusions: Fatty acid analysis of red blood cells is a good measure of compliance with supplement
consumption. However, fatty acid analysis of white blood cells is needed to correlate changes in fatty acid
composition of white blood cells with other biochemical changes in the white blood cells.
Trial Registration: ClinicalTrials.gov NCT00899353.
Introduction
Humans are unable to synthesize the omega 3 or omega
6 bonds, thus, omega-3 and omega-6 fatty acids are
essential fats which we must obtain from food. The
ratio of omega-3 to omega-6 fats in the average western
and/or modern diet is heavily weighted in favor of
omega-6 [1]. Omega-3 deficiencies have been implicated
in growth retardation, neurological dysfunction, and
excessive blood clotting [1]. In recent years, results from
increasing numbers of in vitro and in vivo studies have
demonstrated that omega 3 fatty acids incorporated in
cell culture media or in the diet of the animals can sup-
press the growth of cancers [summarized in [2]]. When
human clinical trials to determine the ability of omega 3
fatty acids to alter growth or response to chemothera-
peutic interventions of cancers are initiated, it will be
essential to determine the omega 3 intake of individuals
in the trial to correlate with endpoints of efficacy. It will
also be useful to determine the omega 3 incorporation
in specific tissues to correlate change in fatty acid com-
position of the tissue with response to therapy.
A commonly used measure of intake and incorpora-
tion of dietary or supplementary fatty acids into cells is
the gas chromatographic analysis of lipid composition of
the specimen [3,4]. In future clinical trials, specific tis-
sues or cells of interest may be difficult or highly inva-
sive to obtain or of limited availability, however,
procuring blood specimens is a relatively non-invasive
procedure. Assessing the composition of red or white
blood cells has been used as a marker of omega 3 fatty
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any medium, provided the original work is properly cited.acid intake in previous reports [3,4]. In our animal stu-
dies, we have reported fatty acid composition of tissues
as a marker for dietary consumption of omega 3 fatty
acid [5-7]. It should be noted that change in fatty acid
composition due to diet was different for different tis-
sues, i.e. the composition of tumor, liver and fat all
changed in response to diet but the magnitude of
change was unique to each tissue [7].
We are performing pilot studies for a human clinical
trial. In this trial, patients with early stage chronic lym-
phocytic leukemia (esCLL) received an omega 3 fatty acid
supplement in increasing doses with the immediate goal
of reducing expression of nuclear factor kappa B. Our
long term goal (which cannot and will not be assessed in
this pilot study) is delaying progression of disease or
increasing the response of the patients to chemotherapy
when they do progress to the point of needing che-
motherapy. The white blood cells (WBCs) of these
patients are far fewer in the blood than the red blood
cells (RBCs), thus we wondered if the fatty acid composi-
tion of RBCs might accurately indicate incorporation of
omega 3 fatty acids in the WBCs. In this report, we
address the: 1) rate of change in the omega 3 composi-
tion of RBCs and WBCs following omega 3 fatty acid
consumption and 2) comparability of RBC and WBC
composition before and after supplementation. Previous
papers have shown that the fatty acid compositions of
both RBCs [3,8] and WBCs [9,10] change in response to
omega 3 fatty acid consumption but to our knowledge
there are not reports that compare baseline RBCs and
WBCs fatty acid compositions or compare the change in
RBCs fatty acid composition to the change in WBCs fatty
acid composition to assess the value of using change in
RBC fatty acid composition as a surrogate for change in
WBC fatty acid composition in future clinical trials.
Results
Baseline fatty acid composition of red and white
blood cells
The fatty acid compositions of red and white blood cells
of patients at baseline are compared in Figure 1. Two
way analyses of variance followed by Bonferroni postt-
ests showed that the steric acid fraction was significantly
less and the arachidonic acid fraction was significantly
higher in RBCs than in WBCs. There were no other sig-
nificant differences.
Red blood cells response to omega 3 supplement
The fatty acid compositions of RBCs of patients at base-
line and after consuming 3, 6 or 9 capsules of omega 3
supplement for one month are shown in Figure 2. As
expected, linear regression analyses showed there were
significant dose responsive decreases in the omega 6 fatty
acids: (slope mean ± SE % per capsule, p value for slope
of line is significantly different from a slope of 0, r
2 = cor-
relation coefficient) linoleic acid (slope = -0.1124 ±
0.01257, p = 0.01, r
2 = 0.97) and arachidonic acid
(slope = -0.5956 ± 0.08963, p = 0.02, r
2 = 0.96). There
were significant, dose responsive increases in the omega
3 fatty acids: EPA (slope 0.4924 ± 0.01134, p = 0.0005, r
2
= 0.99), DPA (slope 0.4690 ± 0.03361, p = 0.005, r
2 =
0.99) and DHA (slope 0.3593 ± 0.04765, p = 0.017, r
2 =
0.97). There were no other significant linear regressions
for the other measured fatty acids.
Repeated measures two way analyses of variance was
used to determine significant differences in the indivi-
dual omega 6 and omega 3 fatty acids of RBCs between
baseline and after consumption of 3, 6 or 9 capsules of
supplement for one month to determine the minimum
dose required for a mathematically significant change.
The fraction of arachidonic acid in RBCs was signifi-
cantly less than baseline after consumption of 3 or more
(p < 0.05) capsules per day. The fractions of EPA (p <
0.01), DPA (p < 0.05) and DHA (p < 0.05) in RBCs were
significantly more than baseline after consumption of 6
or more capsules per day for one month.
White blood cells response to omega 3 supplement
The fatty acid compositions of WBCs from patients at
baseline and after consuming 3, 6 or 9 capsules of
Figure 1 Baseline composition of red and white blood cells.
The % compositions (mean ± SEM) of ten assayed lipids at baseline
(without omega 3 supplement) of red and white blood cells are
shown. Two way analyses of variance followed by Bonferroni
posttests showed that the steric acid fraction was significantly less
and the arachidonic acid fraction was significantly higher in red
blood cells than in white blood cells at baseline.
EPA - eicosapentaenoic acid; DPA - docosapentaenoic
acid; DHA - docosahexaenoic acid.
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T h ec h a n g ei nf a t t ya c i dc o m p o s i t i o no ft h eW B C si n
response to the omega 3 supplement was quite different
from that seen for the RBCs. Linear regression analyses
showed that the only significant dose response was that
of DPA (slope 0.4377 ± 0.02766, p = 0.004, r
2 = .99). The
incorporation of both EPA (slope 0.1594 ± 0.05334, p =
0.1, r
2 = 0.82) and DHA (slope 0.1821 ± 0.06349, p = 0.1,
r
2 = 0.80) were not quite dose responsive, probably
because increasing the dose from 6 to 9 capsules did not
increase the amount of EPA and DHA in cell
membranes.
Repeated measures two way analyses of variance was
used to determine significant differences in the indivi-
dual omega 6 and omega 3 fatty acids of WBCs between
baseline and after consumption of 3, 6 or 9 capsules of
Figure 2 Lipid composition of red blood cells. The % compositions (mean ± SEM) of ten assayed lipids are shown. Omega 6 and omega 3
species are identified by the bracket over the top of each set. Repeated measures analyses of variance followed by Bonferroni posttests were
used to determine significant changes from the baseline fraction of each fatty acid. Significant differences from baseline following each dose of
omega 3 supplement are shown by: * - p < 0.05; ** p < 0.01; *** - p < 0.001. EPA - eicosapentaenoic acid; DPA - docosapentaenoic acid; DHA -
docosahexaenoic acid.
Figure 3 Lipid composition of white blood cells. The % compositions (mean ± SEM) of ten assayed lipids are shown. Omega 6 and omega 3
species are identified by the bracket over the top of each set. Repeated measures analyses of variance followed by Bonferroni posttests showed
that there were no significant changes from the baseline fraction of individual fatty acids. EPA - eicosapentaenoic acid; DPA - docosapentaenoic
acid; DHA - docosahexaenoic acid.
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cally significant changes in omega 6 or omega 3 fatty
acids in WBCs membranes.
Change in sum of omega 3 fatty acids for RBCs and WBCs
Figure 4 illustrates the increases from baseline in the
total fraction of omega 3 fatty acids (sum of ALA, EPA,
DPA and DHA) in membranes of red and white blood
cells after consumption of 3, 6 or 9 capsules per day for
one month. Three points are clear from these graphs: 1)
RBCs incorporate a higher fraction of omega 3 fatty
acids than WBCs; 2) Figure 4A shows that the incor-
poration of omega 3 in RBCs was linear (slope = 1.17%/
capsule, r
2 = .99) and dose responsive; 3) The incorpora-
tion of omega 3 in WBCs was not linear and was at a
slower rate than RBCs. The best linear fit for incorpora-
tion of omega 3 in WBCs had a slope of 0.47%/capsule
(R
2 = 0.77), less than 1/2 the slope for incorporation of
omega 3 in RBCs. As shown in Figure 4-B, a non linear
fit was a better fit for the incorporation of omega 3 fatty
acids in WBCs. Two way ANOVA indicated a signifi-
cant difference due to cell type (p = 0.0078), that is, the
omega 3 fraction in WBCs was always less than the
omega 3 fraction in RBCs.
Discussion
It is important to have some measure of compliance in
clinical trials, whether the test substance is a drug or
consumption of a dietary supplement. Results in pre-
vious papers have demonstrated that the fatty acid com-
position of both RBCs [3,8] and WBCs [9,10] does
change in response to supplementation of the diet with
omega 3 fatty acids. It has been reported that the com-
position of RBCs is less variable and thus a better mar-
ker for longer term consumption than plasma [11].
However, in designing the clinical trial for which these
specimens were obtained we could not find comparisons
of changes in WBC and RBC fatty acid compositions in
response to an omega 3 supplement. It was important
to us to know that the omega 3 supplement was being
incorporated into RBCs and into WBCs so that we
could assess compliance with supplement consumption
in our patients and so that we could later relate the
changes in fatty acid composition in the tumor cells (i.
e., early stage chronic lymphocytic leukemia) with other
measured parameters.
The results reported herein indicate that the question
determines whether the fatty acid composition of RBCs
or WBCs is the best marker. If the question is about
patient compliance with the consumption of the omega
3 supplement, then the fatty acid composition of RBCs
is clearly a good marker. The increase of total omega 3
content in the RBCs was linearly related to consumption
of the omega 3 supplement. We stressed to the patients
that if they could not take an increased dose of the sup-
plement, that was fine, but we did need to know the
actual consumption of capsules. Our patients reported
compliance with the prescribed dose of supplement or
reported the actual reduction in consumption. Pill
counts supported those reports.
On the other hand, the fatty acid composition of the
WBCs, obtained from the same blood specimen as the
RBCs did not show a dose responsive increase in omega
3 fatty acids. The fraction of omega 3 fatty acids showed
Figure 4 Change in total omega 3 in red and white blood cells.
The change in the sum of % compositions of omega 3 fatty acids in
red or in white blood cells following consumption of 3, 6 or 9
capsules of omega 3 supplement for one month is shown. A. Linear
regression was used to determine the dose responsive change in
omega 3 fatty acids in red or white blood cell membranes. For red
blood cells, there was a significant linear regression, r
2 = 0.99, slope =
1.17%/capsule. The regression fit was not significant for white blood
cells. The correlation coefficient for a best fit line was 0.77 with a
slope of 0.47%/capsule. B. Non-linear regression was a better fit to
the change in lipid composition of white blood cells.
Witte et al. Lipids in Health and Disease 2010, 9:31
http://www.lipidworld.com/content/9/1/31
Page 4 of 7the biggest increase from baseline to 3 capsules per day,
an increase of 3.2%. The increase from 3 to 6 capsules
was less than half as much, an additional 1.3% to a total
of 4.5% of the total fatty acids were omega 3. There was
no additional increase when the consumption of the
omega 3 supplement was increased to 9 capsules per
day. Clearly the fatty acid composition of the WBCs
would not be a good indicator of compliance with con-
sumption of the supplement in future clinical trials.
These results may also help us determine dosage for
future clinical trials in which omega 3 fatty acid supple-
mentation is tried as an adjuvant for chemotherapy. Ani-
mal studies indicate that supplementation of the diet
with omega 3 fatty acids increases the efficacy of chemo
and radiation therapy [12-21]. Incorporation of the
omega 3 fatty acids into cell membranes is required for
the activity of the omega 3. Usually only one dose of
omega 3 was incorporated in the diet for animal studies
rather than a range of doses to determine if there was a
dose response. The drug paradigm for chemotherapy is
to use the largest dose the patient can tolerate without
detrimental side effects. However, the results shown here
indicate that 9 capsules per day did not result in more
omega 3 in WBCs than did 6 capsules per day for one
month. We do not know if more than 9 capsules per day
would result in another increase in omega 3 in the
WBCs. The reason the number of patients at 9 capsules
per day is small is that, even though there were few
reported side effects, few patients were willing to take 9
capsules per day. If patients will not take the supplement
if does not matter if more would have been better. Our
results indicate that the fraction of omega 3 fatty acids in
WBC cell membranes was the same after 6 capsules of
this supplement as after 9 capsules of the supplement.
Several questions are still unanswered: 1)What is the
rate of disappearance of omega 3 after discontinuing the
omega 3 supplement? 2) Once a high level of omega 3
is reached in the WBCs membranes, can this level be
maintained with a smaller dose of supplement? These
questions will be important to answer for future clinical
trials with the least burden to the patients.
Conclusions
In conclusion, at baseline, there was little difference
between red blood cells and white blood cells in fatty
acid composition. The fatty acids composition of RBCs
is a dose responsive indicator of omega 3 consumption
but the fatty acid composition of WBCs does not
change linearly with dose. Because of the differences
between RBCs and WBCs in dose response, the compo-
sition of the WBCs must be assessed if one wants to
relate further biochemical changes to the amount of
omega 3 fatty acids in the cell membranes.
Methods
IRB and obtaining informed consent
The Marshall University Institutional Review Board
reviewed and approved the protocol for this study under
a Federal Wide Assurance (FWA #00002704) with the
Office of Human Research Protections. The purpose
and possible risks or benefits were explained to all
research participants prior to obtaining signed informed
consent from all participants. Blood was obtained at the
same time as blood was being obtained for routine clini-
cal tests.
Subject population
All patients presenting with early stage chronic lympho-
cytic leukemia were invited to participate in the pilot
trial. Patients expressing interest in participating in the
trial were then given full details of the study and
informed, written consent was obtained.
Experimental design
The experimental design is shown in Table 1. After
obtaining informed consent, two 7 ml tubes of EDTA
anticoagulated blood were obtained (time 0) as a base-
line and at each subsequent monthly visit. Fatty acid
compositions results up to consumption of 9 capsules
per day for one month are reported in this paper.
Results are from 11 patients at baseline, the same 11
patients after consuming 3 capsules per day for one
month, 9 of those patients after consuming 6 capsules
per day for one month and 3 of the same patients after
consuming 9 capsules per day for one month.
Description of omega 3 supplement
The supplement was a commercially available (Res-Q,
N3 Oceanic, Palm, PA) fish oil concentrate prepared by
molecular distillation. It is free from pollutants, PCB’s,
pesticides and mercury. It is available in capsule or
liquid form. Each capsule contained about 400 mg of
eicosapentaenoic acid (EPA), 300 mg of docosapentae-
noic acid (DHA) and 100-150 mg of other omega 3 fatty
acids. Thus, consumption of 3, 6, or 9 capsules/day
yielded 2.1 g, 4.2 g, or 6.3 g/day of EPA+DHA,
Table 1 Experimental design
Time 0 Month 1 Month 2 Month 3 Month 4
Obtain consent, base
blood, No n-3
Second baseline Start
n-3 at 3 caps/day,
Draw 3 caps specimen
Increase to 6 caps/day,
Draw 6 caps specimen
Increase to 9 caps/day,
Draw 9 caps
specimen
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tolerated dose of 13.1 g/day EPA+DHA reported by
Burns et al. [22]. Each patient started with a dose of 3
capsules per day (1/meal). Dosage was increased to 6
capsules and then to 9 capsules per day (up to 3/meal)
at monthly intervals. Potential dose limiting events were
diarrhea, stomach upset or dislike of taking the capsules.
Specimen handling
An EDTA anticoagulated blood specimen (7 ml) was
obtained from the participant at each regular doctor
visit and was placed on ice until retrieved by laboratory
personnel (within 2-hours of collection). The sample
was centrifuged at 400 g for 10 minutes and about 2 ml
of plasma was removed, divided to 0.5 ml aliquots and
stored at -80°C for future assay. The buffy coat, some
plasma and adjacent red blood cells were removed. A
Ficoll-Paque (GE Healthcare, Piscataway, NJ) gradient
was used to isolate WBCs, according to manufacturer’s
protocol. WBCs were washed with a glucose containing
balanced salt solution, counted and divided into 5 mil-
lion cell aliquots. Following Ficoll-Paque separation,
greater than 95% of cells were lymphocytes.
White and red blood cell fatty acid composition
The fatty acid compositions of WBCs or RBCs were
assessed using gas chromatography, according to our
routine techniques, prior to initiation of the omega 3
supplement (baseline, time 0) and after consumption of
each dose of the supplement for 1 month. Two hundred
microliters of packed red blood cells or 10
6 white blood
cells were homogenized in distilled water with 0.1% BHT
to prevent fatty acid oxidation. Lipids were extracted
with chloroform/methanol, then methylated. Methylated
lipids were separated and identified using gas chromato-
graphy as previously published [23]. Fatty acid methyl
ester standards (Nu-Chek-Prep, Elysian, MN) were used
for peak identification. The individual fatty acid methyl
esters were reported as the percent of the ten analyzed
methylated fatty acids (area under the curve). We are
especially interested in total omega 6 fatty acids, linoleic
acid (LA), gamma linolenic acid, 20:3n-6, and arachidonic
acid (AA), and total omega 3 fatty acids, a linolenic acid,
EPA, docosapentaenoic acid (DPA) and DHA.
Statistical Analyses
Prism
© software (Graphpad, Inc., La Jolla, CA) was used
for statistical analyses by linear regression, non-linear
regression, or repeated measures two way analyses of
variance (2-way ANOVA) followed by Bonferroni postt-
ests as detailed in the results. Prism
© was used for pre-
paration of graphs.
Acknowledgements
The authors gratefully acknowledge funding from a pilot grant to WEH from
the Marshall University Cell Differentiation and Development Center funded
by grant number EPS08-05 from the WV-HEPC. We appreciate the excellent
patient recruitment and record keeping by our Research Nurse, Leann Ross,
RN. Finally, the study would not have been possible without the
cooperation of our volunteer patients.
Author details
1Department of Biochemistry and Microbiology, Marshall University School of
Medicine, Huntington, West Virginia, USA.
2Edwards Comprehensive Cancer
Center, Marshall University School of Medicine, Huntington, West Virginia,
USA.
Authors’ contributions
TRW and AJS performed patient sample handling, processing and GC
analyses. OFB was the oncologist and patient physician. OFB and WEH
developed the study together. WEH obtained grant funding and wrote the
manuscript. All authors have read and approved this manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 23 February 2010 Accepted: 22 March 2010
Published: 22 March 2010
References
1. Simopoulos AP: Human requirement for N-3 polyunsaturated fatty acids.
Poult Sci 2000, 79:961-970.
2. Hardman WE: (n-3) fatty acids and cancer therapy. J Nutr 2004,
134:3427S-3430S.
3. Poppitt SD, Kilmartin P, Butler P, Keogh GF: Assessment of erythrocyte
phospholipid fatty acid composition as a biomarker for dietary MUFA,
PUFA or saturated fatty acid intake in a controlled cross-over
intervention trial. Lipids Health Dis 2005, 4(30):30.
4. Damsgaard CT, Frokiaer H, Lauritzen L: The effects of fish oil and high or
low linoleic acid intake on fatty acid composition of human peripheral
blood mononuclear cells. Br J Nutr 2008, 99:147-154.
5. Hardman WE, Moyer MP, Cameron IL: Consumption of an omega-3 fatty
acids product, INCELL AAFA, reduced side-effects of CPT-11 (irinotecan)
in mice. Br J Cancer 2002, 86:983-988.
6. Hardman WE: Dietary canola oil suppressed growth of implanted MDA-
MB 231 human breast tumors in nude mice. Nutr Cancer 2007,
57:177-183.
7. Hardman WE, Avula CPR, Fernandes G, Cameron IL: Three percent dietary
fish oil concentrate increased efficacy of doxorubicin against MDA-MB
231 human breast cancer xenografts. Clin Cancer Res 2001, 7:2041-2049.
8. Harris WS, Pottala JV, Sands SA, Jones PG: Comparison of the effects of
fish and fish-oil capsules on the n 3 fatty acid content of blood cells
and plasma phospholipids. Am J Clin Nutr 2007, 86:1621-1625.
9. Switzer KC, McMurray DN, Chapkin RS: Effects of dietary n-3
polyunsaturated fatty acids on T-cell membrane composition and
function. Lipids 2004, 39:1163-1170.
10. Morlion BJ, Torwesten E, Lessire H, Sturm G, Peskar BM, Furst P, et al: The
effect of parenteral fish oil on leukocyte membrane fatty acid
composition and leukotriene-synthesizing capacity in patients with
postoperative trauma. Metabolism 1996, 45:1208-1213.
11. Harris WS, Thomas RM: Biological variability of blood omega-3
biomarkers. Clin Biochem 2010, 43:338-340.
12. ais-Pont G, Dupertuis YM, Kossovsky MP, Nouet P, Allal AS, Buchegger F,
et al: Omega-3 polyunsaturated fatty acids and ionizing radiation:
combined cytotoxicity on human colorectal adenocarcinoma cells.
Nutrition 2006, 22:931-939.
13. Biondo PD, Brindley DN, Sawyer MB, Field CJ: The potential for treatment
with dietary long-chain polyunsaturated n-3 fatty acids during
chemotherapy. J Nutr Biochem 2008, 19:787-796.
14. Colas S, Paon L, Denis F, Prat M, Louisot P, Hoinard C, et al: Enhanced
radiosensitivity of rat autochthonous mammary tumors by dietary
docosahexaenoic acid. Int J Cancer 2004, 109:449-454.
Witte et al. Lipids in Health and Disease 2010, 9:31
http://www.lipidworld.com/content/9/1/31
Page 6 of 715. Hardman WE, Sun L, Short N, Cameron IL: Dietary omega-3 fatty acids and
ionizing irradiation on human breast cancer xenograft growth and
angiogenesis. Cancer Cell Int 2005, 5:12.
16. Hardman WE, Barnes CJ, Knight CW, Cameron IL: Effects of iron
supplementation and ET-18-OCH3 on MDA-MB 231 breast carcinomas in
nude mice consuming a fish oil diet. Br J Cancer 1997, 76:347-354.
17. Shaikh IA, Brown I, Schofield AC, Wahle KW, Heys SD: Docosahexaenoic
acid enhances the efficacy of docetaxel in prostate cancer cells by
modulation of apoptosis: the role of genes associated with the
NF-kappaB pathway. Prostate 2008, 68:1635-1646.
18. Ikushima S, Fujiwara F, Todo S, Imashuku S: Effects of polyunsaturated
fatty acids on vincristine-resistance in human neuroblastoma cells.
Anticancer Res 1991, 11:1215-1220.
19. Liu QY, Tan BK: Effects of cis-unsaturated fatty acids on doxorubicin
sensitivity in P388/DOX resistant and P388 parental cell lines. Life Sci
2000, 67:1207-1218.
20. Rudra PK, Krokan HE: Cell-specific enhancement of doxorubicin toxicity in
human tumour cells by docosahexaenoic acid. Anticancer Res 2001,
21:29-38.
21. Xue H, Sawyer MB, Field CJ, Dieleman LA, Baracos VE: Nutritional
modulation of antitumor efficacy and diarrhea toxicity related to
irinotecan chemotherapy in rats bearing the ward colon tumor. Clin
Cancer Res 2007, 13:7146-7154.
22. Burns CP, Halabi S, Clamon GH, Hars V, Wagner BA, Hohl RJ, et al: Phase I
clinical study of fish oil fatty acid capsules for patients with cancer
cachexia: cancer and leukemia group B Study 9473. Clin Cancer Res 1999,
5:3842-3947.
23. Hardman WE, Ion G: Suppression of implanted MDA-MB 231 human
breast cancer growth in nude mice by dietary walnut. Nutr Cancer 2008,
60:666-674.
doi:10.1186/1476-511X-9-31
Cite this article as: Witte et al.: RBC and WBC fatty acid composition
following consumption of an omega 3 supplement: Lessons for future
clinical trials. Lipids in Health and Disease 2010 9:31.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Witte et al. Lipids in Health and Disease 2010, 9:31
http://www.lipidworld.com/content/9/1/31
Page 7 of 7